01 Nov, 2012 8th Annual Meeting of the Oligonucleotide Therapeutics Society
At the 8th Annual Meeting of the Oligonucleotide Therapeutics Society, held in Boston October 28-31, 2012, we presented exciting data covering several of the company’s therapeutic programs and delivery platforms.
Therapeutic research highlighted recent clinical and pre-clinical work from our programs in transthyretin-mediated amyloidosis (TTR), hemophilia, hypercholesterolemia, and liver cancer. Click here for presentations.
In addition, Alnylam scientists presented research on the development and evaluation of new delivery modalities. The presentations showcased the design and synthesis of lipid nanoparticles and GalNAc conjugates, as well as the evaluation of their pharmacodynamic and pharmacokinetic properties.